Praxis Precision Medicines, Inc. PRAX Elsunersen — Program-specific expenses
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Praxis Precision Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The official record: Praxis Precision Medicines, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Praxis Precision Medicines, Inc.'s elsunersen — program-specific expenses.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Praxis Precision Medicines, Inc.'s elsunersen — program-specific expenses?
- Praxis Precision Medicines, Inc. (PRAX) reported elsunersen — program-specific expenses of $3.2M in Q1 2026.
- How has Praxis Precision Medicines, Inc.'s elsunersen — program-specific expenses changed year-over-year?
- Praxis Precision Medicines, Inc.'s elsunersen — program-specific expenses increased by 320.1% year-over-year, from $761K to $3.2M.
- What is the long-term trend for Praxis Precision Medicines, Inc.'s elsunersen — program-specific expenses?
- Over 2 years (2023 to 2025), Praxis Precision Medicines, Inc.'s elsunersen — program-specific expenses has grown at a -31.6% compound annual growth rate (CAGR), from $14.6M to $6.83M.
- What does elsunersen — program-specific expenses mean?
- This metric represents the direct costs associated with the research, development, and production activities specifically allocated to the Elsunersen therapeutic program. It captures the financial resources deployed to advance this clinical candidate through its development lifecycle, including manufacturing and service-related expenditures. Monitoring these costs provides insight into the capital intensity and operational efficiency of the firm's specific drug development pipeline.